Biomarkers最新文献_第3页

Digital biomarkers in non-communicable diseases. 非传染性疾病中的数字生物标志物。

IF 2.2 4区医学

Biomarkers Pub Date : 2026-07-01 Epub Date: 2026-06-15 DOI: 10.1080/1354750X.2026.2682425

Louis Agha-Mir-Salim, Elias Grünewald, Felix Balzer, Katarina Braune

{"title":"Digital biomarkers in non-communicable diseases.","authors":"Louis Agha-Mir-Salim, Elias Grünewald, Felix Balzer, Katarina Braune","doi":"10.1080/1354750X.2026.2682425","DOIUrl":"10.1080/1354750X.2026.2682425","url":null,"abstract":"Background: Digital biomarkers-objective, quantifiable physiological and behavioral measures collected through digital tools-enable continuous health assessment and hold promise for precision medicine. With non-communicable diseases (NCDs) being the leading cause of morbidity and mortality worldwide, digital biomarkers can provide early detection, continuous monitoring, and individualized care.Methods: This review examines advances in digital biomarkers across NCD domains, including endocrinology, cardiology, respiratory medicine, neurology, and mental health, with a focus on wearable technologies that continuously capture real-world behavior and physiology.Results: Continuous glucose monitoring in diabetes exemplifies successful clinical translation, while digital biomarkers in cardiology, respiratory medicine, and neurology are at varying stages of validation and adoption. Most digital biomarkers across internal medicine, neurology, and mental health remain in early validation stages. Critical barriers to implementation include limited validation in diverse populations, lack of interoperability, insufficient integration with electronic health records, challenges in multimodal data synthesis, and underdeveloped regulatory pathways. Equity concerns persist as infrastructure, affordability, and capacity-building needs vary globally.Conclusions: Bridging the gap between consumer self-tracking and clinically validated, guideline-compatible digital biomarkers requires rigorous multicenter validation, standardized interfaces, open data models, secure and ethical data infrastructures, and equitable design. Coordinated efforts addressing these challenges are essential to enable digital biomarkers to improve prevention, diagnosis, and management of NCDs.","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"397-405"},"PeriodicalIF":2.2,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148142556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tissue expression profiles of miR-6809 and miR-4753 in triple-negative breast cancer: Novel biomarkers of early detection and staging. miR-6809和miR-4753在三阴性乳腺癌中的组织表达谱：早期检测和分期的新生物标志物

IF 2.2 4区医学

Biomarkers Pub Date : 2026-06-19 DOI: 10.1080/1354750X.2026.2691001

Mohamed Taha, Emad Mekhael, Ahmed Abd-Al Aziz

{"title":"Tissue expression profiles of miR-6809 and miR-4753 in triple-negative breast cancer: Novel biomarkers of early detection and staging.","authors":"Mohamed Taha, Emad Mekhael, Ahmed Abd-Al Aziz","doi":"10.1080/1354750X.2026.2691001","DOIUrl":"https://doi.org/10.1080/1354750X.2026.2691001","url":null,"abstract":"Background: Triple-negative breast cancer (TNBC) remains lethal due to paucity of targetable markers. MicroRNAs are involved in TNBC pathogenesis; however, their clinical translation in TNBC remain limited. We evaluated miR-6809 and miR-4753 expression in TNBC tissues, their potential as diagnostic biomarkers, and their correlations with tumor-related data.Methods: Thirty-seven TNBC and fifteen breast fibroadenoma (BFA) patients were recruited. Histological grading, immunohistochemistry, and RT-qPCR for miRNA profiling were conducted.Results: miR-6809 and miR-4753 were downregulated in TNBC tissues compared to BFA. In TNBC, miR-6809 and miR-4753 were positively correlated. miR-6809 was negatively correlated with TNM staging and tumor grade. miR-4753 was inversely correlated with TNM staging and carcinoma in situ. Both miRNAs showed excellent diagnostic potential. miR-6809 was associated with TNBC risk in the multivariate analysis (OR = 0.0001, 95% CI = 0.00-0.232). Bioinformatics analysis revealed ADIPOR2, CD84, CD86, IL6R, PDGFA, and STAT5A, as integrated targets of both miRNAs, enriched in EGFR tyrosine kinase inhibitor resistance, Th17 cell differentiation, and JAK-STAT signaling.Conclusion: This study highlights miR-6809 and miR-4753 as potential candidate biomarkers for TNBC. miR-6809 showed particular association with TNBC risk, while both miRNAs correlate with TNM staging, suggesting potential prognostic relevance. Further validation studies are required before clinical utility.","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"1-15"},"PeriodicalIF":2.2,"publicationDate":"2026-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148275974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostic value of plasma NfL and GFAP for conversion to Alzheimer's disease and dementia in MCI: a systematic review and robust Bayesian meta-analysis. 血浆NfL和GFAP对MCI患者转化为阿尔茨海默病和痴呆的预后价值：一项系统评价和稳健的贝叶斯荟萃分析

IF 2.2 4区医学

Biomarkers Pub Date : 2026-06-01 Epub Date: 2026-06-18 DOI: 10.1080/1354750X.2026.2633568

Çağrı Özkurt, Pelin Kelicen-Uğur

{"title":"Prognostic value of plasma NfL and GFAP for conversion to Alzheimer's disease and dementia in MCI: a systematic review and robust Bayesian meta-analysis.","authors":"Çağrı Özkurt, Pelin Kelicen-Uğur","doi":"10.1080/1354750X.2026.2633568","DOIUrl":"10.1080/1354750X.2026.2633568","url":null,"abstract":"Background: Accessible biomarkers to predict conversion to Alzheimer's disease and other dementias in Mild Cognitive Impairment (MCI) are urgently needed. Plasma neurofilament light (NfL) and glial fibrillary acidic protein (GFAP) are leading candidates, but their utility remains debated.Objective: We systematically reviewed the prognostic value of plasma NfL and GFAP in MCI using Robust Bayesian Meta-Analysis (RoBMA) to formally model and adjust for publication bias.Methods: We searched major databases through September 2025 for longitudinal cohort studies (Protocol: OSF 10.17605/OSF.IO/974ZD). RoBMA synthesized hazard ratios while adjusting for small-study effects. Risk of bias (QUIPS) and certainty (GRADE) were assessed.Results: We included 63 studies. For plasma GFAP (k = 3), Bayesian meta-analysis found moderate evidence for an association with dementia conversion (HR: 1.58, 95% CrI [1.00, 2.24]; Inclusion BF = 9.03). Conversely, for plasma NfL, the prognostic signal was driven by decisive publication bias (Bias BF > 4,000,000). After bias adjustment, the effect of NfL on conversion was null (HR: 1.00; Inclusion BF = 0.011). Evidence certainty was Low to Very Low.Conclusions: The prognostic value of plasma NfL for dementia conversion appears to be an artifact of publication bias. Plasma GFAP shows a promising but preliminary signal requiring high-quality validation.","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"326-338"},"PeriodicalIF":2.2,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146212008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Changes in concentrations of tobacco specific nitrosamines in saliva in the general population of Barcelona before and after implementation of tobacco control legislation. 烟草控制立法实施前后巴塞罗那普通人群唾液中烟草特异性亚硝胺浓度的变化。

IF 2.2 4区医学

Biomarkers Pub Date : 2026-06-01 Epub Date: 2026-04-26 DOI: 10.1080/1354750X.2026.2657869

Hipólito Pérez-Martín, Cristina Lidón-Moyano, Adrián González-Marrón, Juan Carlos Martín-Sánchez, Marcela Fu, Montse Ballbè, Raúl Pérez-Ortuño, Jose A Pascual, Esteve Fernández, Jose M Martínez-Sánchez

{"title":"Changes in concentrations of tobacco specific nitrosamines in saliva in the general population of Barcelona before and after implementation of tobacco control legislation.","authors":"Hipólito Pérez-Martín, Cristina Lidón-Moyano, Adrián González-Marrón, Juan Carlos Martín-Sánchez, Marcela Fu, Montse Ballbè, Raúl Pérez-Ortuño, Jose A Pascual, Esteve Fernández, Jose M Martínez-Sánchez","doi":"10.1080/1354750X.2026.2657869","DOIUrl":"10.1080/1354750X.2026.2657869","url":null,"abstract":"Context: This study evaluated changes in salivary tobacco-specific nitrosamines (TSNAs) in smokers and non-smokers before and after Spain's smoke-free legislation.Methods: We conducted a longitudinal study of 272 adults in Barcelona, surveyed in 2004-2005 and 2013-2014, spanning the 2006 legislation and its 2011 extension. Saliva samples were analyzed for NNN, NNK, and NNAL, and geometric means with 95% confidence intervals were calculated. Data were stratified by sociodemographics, smoking status, smoking behavior, and anthropometrics. Linear mixed-effects models assessed adjusted percentage changes in TSNA concentrations.Results: At baseline, overall TSNA concentrations were 1.5 [1.2-1.8] pg/mL for NNN, 1.4 [1.3-1.5] pg/mL for NNK, and 0.5 [0.5-0.6] pg/mL for NNAL. Among baseline smokers who quit, TSNAs decreased by -90.5% (NNN), -48.7% (NNK), and -86.2% (NNAL). Continuing smokers showed a 149.8% increase in NNN, while non-smokers showed no significant change.Conclusions: Concentrations of salivary TSNAs declined in those who quit smoking but increased for continuing smokers. Monitoring TSNAs in saliva is useful for assessing legislative impact.","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"249-257"},"PeriodicalIF":2.2,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147670111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy of total antioxidant capacity as biomarker of oxidative stress in response to organochlorine pesticide exposure. 总抗氧化能力作为有机氯农药暴露后氧化应激生物标志物的作用。

IF 2.2 4区医学

Biomarkers Pub Date : 2026-06-01 DOI: 10.1080/1354750X.2026.2674196

Priyanka Jena, Sakti Prasad Pattnayak, Rangabhatla Saishree, Aditya K Panda, B Anjan Kumar Prusty

{"title":"Efficacy of total antioxidant capacity as biomarker of oxidative stress in response to organochlorine pesticide exposure.","authors":"Priyanka Jena, Sakti Prasad Pattnayak, Rangabhatla Saishree, Aditya K Panda, B Anjan Kumar Prusty","doi":"10.1080/1354750X.2026.2674196","DOIUrl":"10.1080/1354750X.2026.2674196","url":null,"abstract":"Background: Total Antioxidant Capacity (TAC) reflects the overall antioxidants in the body, which typically decrease in response to organochlorine pesticide (OCP) exposure, due to an increase in oxidative stress; however, some studies show contrasting results.Purpose: Owing to the inconsistent findings reported from the studies concerning the association of the TAC in OCP-exposed individuals, a meta-analysis is conducted.Methods: A systematic literature survey was conducted through Scopus, MEDLINE, and Web of Science, up to November 2025, to find relevant articles following the PRISMA guideline.Results: The search resulted in 11 articles, with 08 clinical and 04 exposure-based case-control experiments. The pooled results showed a significant negative association of TAC with OCPs (p < 0.01; standardized mean difference of -1.68). Egger's regression revealed no significant publication bias among the studies. The sensitivity analysis encompassing all the studies indicated the absence of any significant changes in the statistics.Conclusion: Our findings indicated that the concentration of TAC was significantly lower in OCP exposed cases, as compared to the controls and/or unexposed counterparts. This suggests that TAC may serve as a potential biomarker of oxidative stress associated with organochlorine pesticide exposure. Also, this analysis calls for additional studies that can strengthen this association.","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"271-278"},"PeriodicalIF":2.2,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147939665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Systemic inflammatory burden at diagnosis predicts survival in Hodgkin lymphoma: a comprehensive evaluation of the Complete Blood Count Score Model. 诊断时的全身性炎症负担预测霍奇金淋巴瘤的生存：全血细胞计数评分模型的综合评估。

IF 2.2 4区医学

Biomarkers Pub Date : 2026-06-01 Epub Date: 2026-05-24 DOI: 10.1080/1354750X.2026.2674784

Salih Sertaç Durusoy, Deniz Mıhçıoğlu, Sema Köse, Pınar Günel Erturhan, Mehmet Yılmaz

{"title":"Systemic inflammatory burden at diagnosis predicts survival in Hodgkin lymphoma: a comprehensive evaluation of the Complete Blood Count Score Model.","authors":"Salih Sertaç Durusoy, Deniz Mıhçıoğlu, Sema Köse, Pınar Günel Erturhan, Mehmet Yılmaz","doi":"10.1080/1354750X.2026.2674784","DOIUrl":"10.1080/1354750X.2026.2674784","url":null,"abstract":"Background: Although systemic inflammation is a well-established prognostic factor in malignancies, composite inflammation-based models remain underexplored in Hodgkin lymphoma (HL). We investigated the prognostic significance of complete blood count (CBC)-derived inflammatory indices and a novel Complete Blood Count Score Model (CBCSM) in patients with HL.Methods: This study included 80 patients diagnosed with HL. Neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), and systemic inflammation response index (SIRI) were calculated at diagnosis. Optimal cut-off values for progression-free survival (PFS) and overall survival (OS) were determined using receiver operating characteristic analysis. Survival outcomes were assessed using Kaplan-Meier analysis.Results: Higher NLR, PLR, SII, and SIRI values were significantly associated with shorter PFS and OS (p < 0.01). While clinicopathological factors age, disease stage, and B symptoms predominantly influenced overall survival, CBC-derived inflammatory indices were also associated with both PFS and OS in survival analyses. The composite CBCSM enabled additional risk stratification, with progressively worse outcomes observed across increasing risk categories.Conclusion: Baseline CBC-derived inflammatory indices and the composite CBCSM may provide clinically meaningful prognostic information in HL. Their simplicity, cost-effectiveness, and routine availability make them potentially useful adjuncts to traditional prognostic factors for risk stratification and individualized patient management.","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"279-287"},"PeriodicalIF":2.2,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147986574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Integrative approaches in lung cancer diagnosis: bridging molecular biomarkers and AI driven imaging. 肺癌诊断的综合方法：连接分子生物标志物和人工智能驱动成像。

IF 2.2 4区医学

Biomarkers Pub Date : 2026-06-01 Epub Date: 2026-03-19 DOI: 10.1080/1354750X.2026.2644329

Purabi Saha, Azra Yasmin, Ritesh Jha, Aarti Passi, Manpreet Kaur, Shammy Jindal, Vikramdeep Monga, Kamya Goyal

{"title":"Integrative approaches in lung cancer diagnosis: bridging molecular biomarkers and AI driven imaging.","authors":"Purabi Saha, Azra Yasmin, Ritesh Jha, Aarti Passi, Manpreet Kaur, Shammy Jindal, Vikramdeep Monga, Kamya Goyal","doi":"10.1080/1354750X.2026.2644329","DOIUrl":"10.1080/1354750X.2026.2644329","url":null,"abstract":"Background: Early and accurate detection of lung cancer remains a major clinical challenge. Conventional diagnostics, including X-ray, tissue biopsy etc., have limited sensitivity for identifying tumors early. Recent advances in molecular biology and computational technologies have significantly transformed lung cancer diagnostics.Methods: This review examines recent developments in biomarker-driven and technology-assisted diagnostic strategies for lung cancer. It highlights clinical relevance of molecular biomarkers, including EGFR, ALK etc., and evaluates emerging approaches like next-generation sequencing (NGS), ctDNA analysis, AI-based analytical tools.Results: Integration of molecular biomarkers into routine diagnostics has improved tumor subtyping and enabled more targeted therapeutic selection. Non-invasive approaches like liquid biopsy facilitate real-time tumor characterization and disease monitoring. In parallel, NGS and multi-omics technologies like genomics, transcriptomics provide comprehensive insights into tumor biology and tumor microenvironment. Advances in radiomics and AI-driven image analysis, particularly machine learning and deep learning applied to low-dose CT imaging, enhancing early detection and risk stratification. AI-powered detection systems and predictive models further support clinical decision-making.Conclusions: The convergence of biomarker research, multi-omics technologies, and AI-driven analytics is reshaping lung cancer diagnostics toward more precise and personalized approaches. However, challenges related to data standardization, interpretability, clinical validation, and ethical considerations must be addressed to enable widespread clinical implementation.","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"295-325"},"PeriodicalIF":2.2,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147455428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluating SEPHS2 expression and glutathione peroxidase as biomarkers in recurrent pregnancy loss: a new insight. 评估SEPHS2表达和谷胱甘肽过氧化物酶作为复发性妊娠丢失的生物标志物：新的见解。

IF 2.2 4区医学

Biomarkers Pub Date : 2026-06-01 Epub Date: 2026-04-22 DOI: 10.1080/1354750X.2026.2659525

Mai M Shaker, Eman Reda Galal, Taghreed A Shalabi, Nesma M Elaraby, Fatma Elzahraa Sobhy Ammar, Fatma Alzahraa Mohamed Hassan

{"title":"Evaluating SEPHS2 expression and glutathione peroxidase as biomarkers in recurrent pregnancy loss: a new insight.","authors":"Mai M Shaker, Eman Reda Galal, Taghreed A Shalabi, Nesma M Elaraby, Fatma Elzahraa Sobhy Ammar, Fatma Alzahraa Mohamed Hassan","doi":"10.1080/1354750X.2026.2659525","DOIUrl":"10.1080/1354750X.2026.2659525","url":null,"abstract":"Background: Selenophosphate synthetase 2 (SEPHS2) activates selenophosphate, a donor for selenocysteine required for glutathione peroxidase (GPX) production. GPX protects placental tissue. Dysregulation of SEPHS2 and reduced GPX activity may contribute to oxidative stress-mediated placental dysfunction in recurrent pregnancy loss (RPL).Aim: To evaluate SEPHS2 gene expression and plasma GPX levels as prognostic biomarkers in women with idiopathic RPL and their association with oxidative imbalance.Methods: A total of 100 women with idiopathic RPL and 100 healthy women without history of RPL were included. SEPHS2 gene expression was quantified using quantitative reverse transcription polymerase chain reaction (qRT-PCR), and plasma GPX levels were measured using enzyme-linked immunosorbent assay (ELISA).Results: SEPHS2 expression was significantly elevated in the RPL group compared with controls (mean fold change: 14 ± 11.4 vs. 5 ± 8), while plasma GPx levels were markedly reduced in women with RPL (5.57 ± 0.40 vs. 9.53 ± 3.28; P < 0.001, 95% CI: 3.32-4.62). These findings indicate an association between increased SEPHS2 expression, reduced antioxidant activity, and recurrent pregnancy loss.Conclusion: Elevated SEPHS2 expression suggests disrupted selenoprotein-mediated antioxidant defense in RPL. SEPHS2 and GPX may serve as prognostic biomarkers.","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"258-265"},"PeriodicalIF":2.2,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147688058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of CD36 expression on survival and febrile neutropenia in patients with acute myeloid leukemia. CD36表达在急性髓性白血病患者生存和发热性中性粒细胞减少中的作用。

IF 2.2 4区医学

Biomarkers Pub Date : 2026-06-01 Epub Date: 2026-05-25 DOI: 10.1080/1354750X.2026.2672956

Ahmet Yigitbasi, Elif Gulsum Umit, Bahar Kandemir, Ahmet Muzaffer Demir

{"title":"The role of CD36 expression on survival and febrile neutropenia in patients with acute myeloid leukemia.","authors":"Ahmet Yigitbasi, Elif Gulsum Umit, Bahar Kandemir, Ahmet Muzaffer Demir","doi":"10.1080/1354750X.2026.2672956","DOIUrl":"10.1080/1354750X.2026.2672956","url":null,"abstract":"Background: Acute myeloid leukemia (AML) is a clonal malignancy characterized by impaired hematopoietic differentiation. CD36 is a transmembrane glycoprotein receptor for phospholipids, lipoproteins, and long-chain fatty acids, and has been implicated in chemoresistance. In this AML cohort we evaluated CD36 expression and its association with febrile neutropenia (FEN) and overall survival (OS) as a potential biomarker of infectious risk.Purpose: To assess whether CD36 expression may be associated with FEN and OS in AML.Methods: We conducted a retrospective single-center cohort study of patients with AML, evaluating flow cytometric CD36 expression and its associations with FEN and OS during follow-up.Results: Among 41 AML patients (median age, 61 years; 46.3% male), CD36 expression was <20% in 20 (48.8%) and ≥20% in 21 (51.2%). FEN occurred in 34 patients (82.9%), including 20/21 (95.2%) in the CD36 ≥ 20% group (p = 0.032). Patients with CD36 expression ≥20% also exhibited shorter OS and a higher hazard of death on univariable Cox regression (HR 3.161, 95% CI 1.276-7.827; p = 0.013).Conclusion: Higher CD36 expression in AML may be associated with more frequent FEN and reduced OS, suggesting its potential clinical relevance as a biomarker of infection-related vulnerability and adverse prognosis.","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"266-270"},"PeriodicalIF":2.2,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147926028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Circulating KIM-1 as a prognostic biomarker and predictor of systemic treatment response in renal cell carcinoma: a systematic review and meta-analysis. 循环KIM-1作为肾细胞癌系统治疗反应的预后生物标志物和预测因子：一项系统综述和荟萃分析

IF 2.2 4区医学

Biomarkers Pub Date : 2026-06-01 Epub Date: 2026-05-04 DOI: 10.1080/1354750X.2026.2664868

Toni Febriyanto, Yosua Yerico Hutajulu, Noka Yogahutama, Wynne Wijaya, Ahmad Zulfan Hendri

{"title":"Circulating KIM-1 as a prognostic biomarker and predictor of systemic treatment response in renal cell carcinoma: a systematic review and meta-analysis.","authors":"Toni Febriyanto, Yosua Yerico Hutajulu, Noka Yogahutama, Wynne Wijaya, Ahmad Zulfan Hendri","doi":"10.1080/1354750X.2026.2664868","DOIUrl":"10.1080/1354750X.2026.2664868","url":null,"abstract":"Background: Renal cell carcinoma (RCC) exhibits heterogeneity and variable responses to systemic therapy. Kidney injury molecule-1 (KIM-1) has emerged as a biomarker in RCC, but its prognostic and treatment-response value has not been quantified. This review and meta-analysis evaluated whether baseline KIM-1 predicts survival in RCC and whether post-treatment changes in KIM-1 reflect systemic therapy response.Methods: A search of PubMed, Embase and the Cochrane Library was conducted through November 2025. Eligible studies measured serum or plasma KIM-1 in RCC and reported survival or treatment-response outcomes. Hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled.Results: Eight studies including 3002 patients met inclusion criteria. High baseline KIM-1 was associated with worse survival (HR 1.44, 95% CI 1.27-1.62) and disease-free survival (HR 1.72, 95% CI 1.45-2.04), with no heterogeneity (I2 = 0%). Declines in KIM-1 after systemic therapy were associated with improved progression-free survival (HR 0.55, 95% CI 0.32-0.94; I2 = 71.5%) and improved disease-free survival (HR 0.66, 95% CI 0.50-0.87).Conclusions: Elevated baseline circulating KIM-1 indicates higher RCC recurrence and mortality risk, while post-treatment declines may reflect therapeutic response. Preliminary evidence suggests KIM-1 prognostic and predictive value for RCC biomarker, though further validation is required due to lower certainty.","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"339-349"},"PeriodicalIF":2.2,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147810537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0